Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Short Interest Update

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) saw a significant drop in short interest in January. As of January 15th, there was short interest totaling 13,222 shares, a drop of 26.7% from the December 31st total of 18,047 shares. Based on an average daily trading volume, of 59,945 shares, the short-interest ratio is currently 0.2 days. Approximately 0.2% of the company’s stock are sold short. Approximately 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 59,945 shares, the short-interest ratio is currently 0.2 days.

Hedge Funds Weigh In On Chemomab Therapeutics

A hedge fund recently bought a new stake in Chemomab Therapeutics stock. Kestra Private Wealth Services LLC bought a new position in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 51,710 shares of the company’s stock, valued at approximately $85,000. Kestra Private Wealth Services LLC owned 0.84% of Chemomab Therapeutics as of its most recent filing with the Securities and Exchange Commission. 46.05% of the stock is owned by hedge funds and other institutional investors.

Chemomab Therapeutics Trading Down 1.5%

Shares of CMMB traded down $0.03 during mid-day trading on Tuesday, hitting $1.65. 62,878 shares of the company’s stock were exchanged, compared to its average volume of 59,001. Chemomab Therapeutics has a fifty-two week low of $1.53 and a fifty-two week high of $8.76. The business’s 50 day moving average is $1.98 and its two-hundred day moving average is $2.80. The firm has a market capitalization of $10.12 million, a P/E ratio of -0.56 and a beta of 0.51.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on CMMB shares. Zacks Research lowered Chemomab Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 18th. Wall Street Zen raised shares of Chemomab Therapeutics to a “hold” rating in a report on Saturday, October 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Chemomab Therapeutics in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Chemomab Therapeutics currently has an average rating of “Hold” and a consensus target price of $26.50.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.